Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.
Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.
Makes intermediates to a customer's own molecule under long-term contracts, often exclusive, so the buyer supplies the design and Anupam the chemistry and plant capacity. A small number of global agrochemical companies account for much of sales.
In one line: A specialty-chemical custom manufacturer for agrochem/pharma.
Moat: narrow (process know-how, customer qualification). Long-term supply contracts tied to a customer's registered molecule create switching costs.
Headquarters: Surat, India · Founded: 1984 · Employees: 2,931
Size Anupam Rasayan India (ANURAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.61B, the 448th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,321 on 18 Nov 2026.
Performance Over six months the shares fell 3.0%, against -7.7% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 23.8% over the last twelve months (peer median +6.6%); the operating margin is 16.3% (peer median 12.0%).
Valuation It trades at 49.9× forward earnings against a peer median of 23.8× (3rd most expensive of 15).
Capital Return on invested capital runs 11.2 points below its cost of capital (14.4% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.1B | ₹23.6B | ₹14.3B | ₹14.7B | ₹15.9B |
| Revenue growth | — | +65% | -2% | -8% | — |
| Gross profit | ₹9.41B | ₹5.31B | ₹4.05B | ₹4.02B | ₹4.51B |
| EBITDA | ₹6.14B | ₹5.40B | ₹4.03B | ₹3.81B | ₹4.28B |
| Net income | ₹1.80B | ₹1.70B | ₹933M | ₹1.29B | ₹1.81B |
| Free cash flow | n/a | -₹3.57B | -₹5.45B | -₹7.39B | ₹141M |
| Capital expenditure | n/a | ₹5.55B | ₹4.10B | ₹7.16B | ₹2.21B |
| Total debt | ₹25.3B | ₹18.7B | ₹14.3B | ₹10.7B | ₹8.22B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Anupam Rasayan India ANURAS.NS | $1.61B | -3% | +24% | 16% | 49.9× | n/a |
| PI Industries PIIND.NS | $2.63B | -48% | -15% | 13% | 31.6× | n/a |
| Srf SRF.NS | $7.77B | -7% | +20% | 19% | 30.0× | 25.5% |
| Navin Fluorine International NAVINFLUOR.NS | $5.66B | +45% | +46% | 30% | 51.6× | 37.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANURAS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.1% | -3.9% | highest of 21 |
| 6-month return | -3.0% | -7.7% | 9th highest of 20 |
| Distance from 52-week high | -6.6% | -33.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +23.8% | +6.6% | 4th highest of 20 |
| Operating margin | 16.3% | 12.0% | 7th highest of 20 |
| Forward P/E | 49.9× | 23.8× | 3rd most expensive of 15 |
| ROIC minus cost of capital | -11.2 pp | +1.2 pp | 4th lowest of 21 |
| EV / EBITDA | 30.7× | 17.1× | 2nd most expensive of 7 |
| Net debt / EBITDA | 2.8× | -1.1× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |